Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep

M. Ratajczak-Enselme¹, J.-P. Estebe², F.-X. Rose¹, E. Wodey², J.-M. Malinovsky¹, F. Chevanne¹, G. Dollo¹, C. Ecoffey² and P. Le Corre¹*

¹Laboratoire de Pharmacie Galénique, Biopharmacie et Pharmacie Clinique, UPRES 3892, Faculté des Sciences Pharmaceutiques et Biologiques and ²Département d’anesthésie 2, Faculté des Sciences Médicales, Université de Rennes 1, 35043 Rennes Cedex, France

*Corresponding author. E-mail: pascal.le-corre@univ-rennes1.fr

Background. Local vasoconstriction induced by epinephrine added to epidural local anaesthetics has been shown to improve their quality and duration of action in several clinical reports. There are several assumptions on the mechanisms. This study was designed to evaluate the influence of epinephrine on transmeningeal uptake of epidurally administered ropivacaine and bupivacaine by measuring local anaesthetic concentrations in the epidural and intrathecal spaces and in plasma.

Methods. Ropivacaine (50 mg) and bupivacaine (30 mg) were administered epidurally in sheep with and without epinephrine (75 µg). A microdialysis technique was used to simultaneously measure epidural and intrathecal drug concentrations. Resulting dialysate and plasma concentrations were used to calculate pharmacokinetic parameters for ropivacaine and bupivacaine.

Results. Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (SD 0.1) vs 0.4 (0.1) ml min⁻¹] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min⁻¹]. The resultant increase in epidural area under the concentration–time curves (31% for ropivacaine and 52% for bupivacaine) was also observed in the intrathecal space (21% increase for ropivacaine and 37% for bupivacaine). There was no significant influence of epinephrine on ropivacaine plasma pharmacokinetics. Plasma Cmax for bupivacaine was decreased.

Conclusions. These results show that epinephrine decreases the clearance and distribution processes involved in epidural disposition of ropivacaine and bupivacaine, leading to an increased uptake into the intrathecal space with an apparent more pronounced effect for bupivacaine.

Br J Anaesth 2007; 99: 881–90

Keywords: anaesthetics local, bupivacaine; anaesthetics local, ropivacaine; cerebrospinal fluid; measurement techniques, microdialysis; pharmacokinetics, uptake

Accepted for publication: July 17, 2007
systemic toxicity. Another explanation is an additive or synergistic analgesic effect via activation of α2-adrenergic receptors.12 The effect of epinephrine has frequently been assessed from its impact on the plasma concentrations of local anaesthetics. However, such modifications may result from an increase in plasma clearance and in volume of distribution caused by the systemic action of absorbed epinephrine,13 and not from a modification of the systemic uptake.3

Simultaneous analysis of local anaesthetic concentrations in the epidural and intrathecal spaces, and plasma, could help to clarify the mechanism(s) by which epinephrine improves the action of epidurally administered local anaesthetic. The effect of epinephrine is likely influenced by different factors such as drug physico-chemical characteristics and their concentrations or the site of injection. For that reason, we decided to compare the effects of epinephrine on bupivacaine and ropivacaine disposition, two local anaesthetics with different physico-chemical properties. Compared with ropivacaine, bupivacaine is characterized by higher lipid solubility and a higher uptake into neural tissue.14 15 Moreover, ropivacaine has an intrinsic vasoconstrictor effect, in contrast to bupivacaine.16–19 The main goal of our study, carried out in a sheep model using simultaneous epidural-intrathecal microdialysis, was to describe the influence of epinephrine on epidural, intrathecal, and systemic local anaesthetic pharmacokinetics.

Methods

Chemicals

Ropivacaine and bupivacaine (Astra Zeneca, Paris, France) were used as the substance of interest and as an internal standard in the microdialysis technique, one being internal standard for the other and vice versa. Etidocaine (Astra Zeneca, Paris, France) was used as a HPLC internal standard for both drugs. Epinephrine was purchased from Aguettant (Lyon, France). Ringer's solution (NaCl 8.6 g litre⁻¹, KCl 0.33 g litre⁻¹, CaCl₂·2H₂O 0.3 g litre⁻¹, pH 7.0) was used as perfusion fluid during the microdialysis experiments. All reagents were of analytical grade.

Microdialysis

Microdialysis was performed using a CMA 102 micro-injection pump coupled to a CMA/20 microdialysis probe (membrane length 10 mm, shaft length 140 mm, 0.5 mm outer diameter, molecular weight cut-off 20 kDa). Dialysates were collected by dilution using a CMA 142 microfraction collector (CMA Microdialysis, Solna, Sweden).

During the experiments, microdialysis probes were perfused at 1 µl min⁻¹ with a solution of internal standard (1 mg ml⁻¹ bupivacaine or ropivacaine in a Ringer's solution). After probe insertion in the intrathecal space and epidural space, an in vivo equilibration with determination of relative loss (RL) of internal standard (n=10 for each probe tested) was performed over a period of 45 min. Owing to the high sampling frequency in the in vivo experiments, an accurate collection of micro-volume dialysates was achieved by immersion of the prolongator of the outlet tubing of microdialysis probe into 100 or 200 µl of a 1 µg ml⁻¹ etidocaine solution for intrathecal or epidural probes, respectively. A collection interval of 1 min during the first 15 min of experiment and of 5 min during the further experiment allowed sampling of 1 and 5 µl of dialysate, respectively.

Throughout the experiments, the RL of internal standard was determined in each sample and used to correct dialysate concentrations.

Before and after in vivo implantation, the probes were tested in vitro in order to verify the lack of significant deterioration by comparison with RL of internal standards. The inter-batch variability among microdialysis probes was low. Indeed, the in vitro RL of internal standards checked before in vivo implantation was 0.47 (0.06) and 0.49 (0.04) (n=10) for ropivacaine and bupivacaine, respectively.

Study design

Twelve non-pregnant Lacaunes ewes with a mean age 2.8 (1) yr and weight 55.6 (3.4) kg were used in this experiment. The experimental protocol was approved by the Local Committee of Laboratory Investigation and Animal Care of our institution and achieved in accordance with the rules and guidelines concerning the care and the use for laboratory animal experiments (agreement no. B35-238-21).

Throughout the experiment, the animals were anaesthetized with 1–2% isoflurane in oxygen/air (50/50%). The general anaesthesia was induced with an i.v. injection of thiopental (5–8 mg kg⁻¹) through a catheter inserted in the right jugular vein. Animals were then intubated, and lung ventilation was controlled mechanically [end-tidal CO₂ 35 (5) mm Hg]. Haemodynamic parameters (i.e. ECG and invasive arterial blood pressure) were continuously monitored. When the systolic blood pressure (SBP) decreased to <80 mm Hg, isoflurane administration was reduced, and infusion of 500–1000 ml of hydroxyethyl starch was performed as necessary. An oesophageal thermometer was used to measure body temperature, and a heat lamp was used to maintain body temperature above 37.5°C.

After blunt dissection, a small laminectomy with the removal of a piece of ligamentum flavum was performed at L5–L6 level. The insertion of epidural and intrathecal catheters was performed under visual control by a modified Seldinger technique. In the first step, a puncture of the dura mater was performed with a Tuohy needle (1.5 mm external diameter). Then, after control of free cerebrospinal fluid (CSF) reflux, a guide wire was advanced through the needle.
over 10 cm into the intrathecal space. By sliding it over the guide wire, the Tuohy needle was removed. The custom-made catheter (external diameter of 2.0 mm and length of 120 mm), allowing injections around the tip of the microdialysis probe, was advanced along the guide wire. After removal of the guide wire, the intrathecal microdialysis probe was inserted through the catheter only if CSF reflux was observed. An epidural catheter was inserted using the same technique in order to put the tip of the catheter vis-à-vis to that in the intrathecal space. Epidural microdialysis probe was introduced in the absence of CSF reflux.

At the end of the surgery, the laminectomy and puncture areas were secured with a drop of cyanoacrylate tissue adhesive (Indermil, Tyco Healthcare, Gosport, UK). Then, a small amount of blood was used to occlude the open surgical site, allowing control of liquid back flow (i.e. after local anaesthetics injection and during the experiment period).

The study was performed on 12 animals, divided into two groups receiving ropivacaine or bupivacaine. Ropivacaine hydrochloride (50 mg) or bupivacaine hydrochloride (30 mg) was diluted in 0.9% sodium chloride to a final volume of 15 ml and was injected through the epidural catheter over a period of 1 min. The ratio of dose between epidural bupivacaine and ropivacaine was close to that used in the previous studies, which were based on the minimal local analgesic concentrations of these drugs.20 21 The animals first received the plain drug and then at 2 h intervals the drug with epinephrine (75 mg). A third control injection was performed with one drug (i.e. ropivacaine) and was compared with the first injection to check for the reproducibility of the model (Fig. 1).

Epidural and intrathecal microdialysis sampling after all injections was achieved according to the following schedule: before administration, every minute during the first 15 min and then every 5 min to the end of experiment (120 min). A venous catheter was inserted in the left jugular vein for blood sampling and administration of maintenance fluid. Blood samples were collected before injection and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 20, 30 min and every 15 min until 120 min.

At the end of the experiment, the animals were euthanized with simultaneous i.v. injection of thiopental, potassium chloride, and pancuronium.

The epidural and intrathecal microdialysis probes were removed from their respective catheters to check for the CSF reflux from the intrathecal space and for the lack of the reflux from the epidural space. This allowed confirmation of the good positioning of the probes.

**Chromatographic analysis and drug assay**

The separation and quantification of the local anaesthetics in the intrathecal or epidural dialysates, and in plasma samples, were carried out using a high-pressure liquid chromatographic with UV absorbance detection ($\lambda=205$ nm). Aliquots of 20 or 50 µl (for intrathecal or epidural samples, respectively) of the dialysate dilutions were immediately injected onto the chromatographic system. Ropivacaine and bupivacaine were extracted from plasma according to a previously published method with slight modifications.22 Briefly, 0.5 ml of plasma was alkalinized with 50 µl of 1 M NaOH and 3 ml of n-heptane was added; after horizontal shaking (3 min) and centrifugation (3 min at 3500 g), the organic phase was transferred to a conical vial containing 50 µl of 0.05 M H$_2$SO$_4$. After similar shaking and centrifugation, the organic phase was discarded and the aqueous phase was buffered with 10 µl of 0.5 M K$_2$HPO$_4$ and 40 µl were injected onto the chromatographic system. The chromatographic system consisted of a Milton Roy model spectromonitor-3 UV detector (LDC Milton Roy, Riviera Beach, FL, USA), a Waters Model 600 pump, a Waters Model 717 automatic injector, and a Waters Empower-Pro data acquisition system (Waters Assoc., Milford, MA, USA). The analytical chromatographic column was a Lichrocart-Lichrospher RP-B Merck cartridge (length 125 mm, internal diameter 3 mm). The flow rate was 0.5 ml min$^{-1}$, and the temperature was maintained at 30°C. The mobile phase consisted of a mixture of acetonitrile and pH 2.1, 0.01 M sodium dihydrogen phosphate (23:77).

**Data analysis**

Maximum plasma, epidural, and intrathecal concentrations (Cmax), the corresponding time (Tmax), and the last measured concentrations (Clast) of ropivacaine and bupivacaine were derived from raw data. A non-compartmental analysis was applied to the epidural, intrathecal, and plasma concentrations after epidural administration.

---

**Fig 1** Experimental protocol for the study.
WinNonlin Pro software (Pharsight, USA) was used to determine the area under the concentration–time curve (AUC), volume of distribution (Vss), clearance (Cl), and elimination half-life (T1/2, β). The volume of distribution and clearance are calculated directly if the site of administration and sampling are the same (i.e. in the epidural space). In the intrathecal space and plasma, they can only be calculated when compared with bioavailability; hence, they are expressed as Vss/F and Cl/F, respectively.

Intrathecal, epidural, and plasma drug concentrations after the second and the third injection were corrected by subtraction of the residual concentrations resulting from the previous administrations. Residual concentrations were extrapolated from the last sample point on the basis of the terminal elimination half-life.

**Statistics**

All data are presented as mean (SD). Student’s paired t-test was performed to compare the effect of epinephrine on pharmacokinetic parameters of ropivacaine and bupivacaine. Differences in pharmacokinetic parameters between both drugs were analysed in the epidural space using a Student’s t-test. A P-value of <0.05 was considered as statistically significant.

**Results**

**Haemodynamic data**

No visual CSF leakage was recorded after catheter placement or during the procedure. Compared with baseline haemodynamics determined just before injection (i.e. 60 min after induction of general anaesthesia), no significant differences were observed between groups (bupivacaine vs ropivacaine) with or without epinephrine before epidural administration (Table 1).

After epidural administration of local anaesthetics, SBP and diastolic blood pressure (DBP) decreased slightly, with a significant effect only on DBP after ropivacaine injection. No medical intervention was necessary to restore haemodynamics during the entire procedure, and no significant difference was observed with subsequent administrations of local anaesthetics.

At baseline, there was no difference in heart rate between animals receiving epidural ropivacaine or bupivacaine either with or without epinephrine (Table 2). A slight decrease in heart rate was observed after injection of local anaesthetics with a significant effect only after the first ropivacaine injection [maximum decrease observed at 10 min: 91 (15) beats min⁻¹].

**Influence of epinephrine on pharmacokinetics of ropivacaine and bupivacaine**

**Epidural space**

The individual and mean epidural concentration–time profiles of ropivacaine and bupivacaine after epidural administration with and without epinephrine are presented in Figure 2. The corresponding pharmacokinetic parameters are listed in Table 3. The epidural concentration–time curves showed a low scatter and displayed important differences in the epidural profiles between both drugs. Ropivacaine epidural clearance and volume of distribution were significantly lower than those observed with bupivacaine. Interestingly, the terminal elimination half-life (T1/2b) from the epidural space was lower for ropivacaine than for bupivacaine [73.1 (47.8) and 142.5 (67.8) min, respectively].

Pharmacokinetic analysis was performed on six animals for each drug. However, we noticed that in the ropivacaine group, one sheep had atypical values for the volume of distribution (very low without epinephrine and very high with epinephrine). The reason for such feature is unknown, and all others parameters such as clearance and T1/2b were close to that obtained for other animals. Adding epinephrine decreased significantly the epidural clearance of ropivacaine and the volume of distribution of bupivacaine. Hence, co-administration of epinephrine increased the epidural AUC of both drugs. Ropivacaine AUC showed a 31% increase (P<0.03) and bupivacaine AUC a 52% increase (P<0.002). Similarly, the last concentrations at 120 min (Clast) were also significantly higher compared with both drugs alone. There was no difference in Cmax with or without epinephrine for ropivacaine and bupivacaine.

The epidural AUC obtained after the third injection (plain ropivacaine) was not statistically different to that obtained after the first injection [53 609 (15 709) vs 61 516 (12 765) μg min ml⁻¹], indicating that epidural

<table>
<thead>
<tr>
<th>Parameters (mm Hg)</th>
<th>Ropivacaine</th>
<th>Bupivacaine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First injection plain</td>
<td>Second injection with epinephrine</td>
</tr>
<tr>
<td></td>
<td>SBP</td>
<td>DBP</td>
</tr>
<tr>
<td>Baseline value</td>
<td>141 (10)</td>
<td>114 (25)</td>
</tr>
<tr>
<td>Value at time of maximal decrease</td>
<td>110 (21)</td>
<td>82 (20)*</td>
</tr>
</tbody>
</table>
drug disposition had returned to normal (without epinephrine).

Intrathecal space

Figure 3 reports the individual and mean CSF concentrations of ropivacaine and bupivacaine after epidural administration with and without epinephrine. CSF non-compartmental pharmacokinetic parameters are listed in Table 4. The observed Tmax in the intrathecal space did not show any significant difference between ropivacaine and bupivacaine [15.2 (8.2) and 13.5 (3.7) min, respectively]. Co-administration of epinephrine influenced the intrathecal pharmacokinetics of both drugs. The AUC and the clast of ropivacaine and bupivacaine were higher with epinephrine. The increase in intrathecal AUC was 21% for ropivacaine (P<0.05) and 37% for bupivacaine (P=0.07). The co-administration of epinephrine also increased the apparent T1/2b of bupivacaine in the intrathecal space.

Plasma

Figure 4 shows the mean and individual plasma concentrations of ropivacaine and bupivacaine after epidural administration with and without epinephrine. The corresponding pharmacokinetic parameters are presented in Table 5.
Venous plasma concentration time plots are characterized by a biphasic pattern with a rather significant scattering. The observed Tmax in plasma did not show any significant difference between ropivacaine and bupivacaine [12 (5) and 13 (4) min, respectively]. Adding epinephrine did not influence plasma pharmacokinetics of ropivacaine. In contrast, the Cmax of bupivacaine with epinephrine was significantly lower than that observed with plain bupivacaine [28 (12) and 45 (21) μg ml\(^{-1}\), respectively]. There was also a trend to decreasing the AUC of bupivacaine with co-administration of epinephrine (\(P\leq0.06\)). The bupivacaine total clearance (\(\text{Cl/F}\)) was lower and apparent T1/2b was higher when co-administrated with epinephrine (\(P<0.05\)), but Tmax was unaffected.

**Discussion**

Spinal disposition of local anaesthetics administrated by the epidural route has been the subject of much discussion...
and speculation. Furthermore, the effect of epinephrine on spinal and systemic concentrations of local anaesthetics has been subjected to debate in preclinical and in clinical studies. Confusion results as a consequence of various data derived either from pharmacodynamic studies suggesting a specific analgesic effect of epinephrine (i.e. α2 adrenergic effect) or from pharmacokinetic studies based only on plasma concentrations. In this work, we report the first investigation, with a simultaneous epidural–intrathecal microdialysis, evaluating the influence of the co-administration of epinephrine on the spinal disposition of ropivacaine and bupivacaine after epidural administration.

However, given the fact that our model requires anaesthetized animals, we could not perform a simultaneous evaluation of pharmacodynamic data on sensory and motor block, and this represents a limitation of our study. Moreover, the duration of experiment has to be limited because of the general anaesthesia (around 7 h post-

### Table 4 Intrathecal pharmacokinetic parameters after epidural administration. *P<0.05 difference between plain ropivacaine and ropivacaine with epinephrine and between plain bupivacaine and bupivacaine with epinephrine

<table>
<thead>
<tr>
<th></th>
<th>Ropivacaine (50 mg)</th>
<th>Bupivacaine (30 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plain</td>
<td>With epinephrine</td>
</tr>
<tr>
<td></td>
<td>9727 (3547)</td>
<td>11 798 (5004)*</td>
</tr>
<tr>
<td></td>
<td>136 (30)</td>
<td>154 (56)</td>
</tr>
<tr>
<td></td>
<td>15.2 (8.2)</td>
<td>18.7 (12.5)</td>
</tr>
<tr>
<td></td>
<td>3.8 (1.7)</td>
<td>2.4 (1.2)*</td>
</tr>
<tr>
<td></td>
<td>349.5 (263.1)</td>
<td>347.73 (176.1)</td>
</tr>
<tr>
<td></td>
<td>60.7 (17.5)</td>
<td>93.7 (56.9)</td>
</tr>
<tr>
<td></td>
<td>43 (18)</td>
<td>67 (29)*</td>
</tr>
<tr>
<td></td>
<td>1688 (994)</td>
<td>2314 (1828)</td>
</tr>
<tr>
<td></td>
<td>36 (27)</td>
<td>40 (36)</td>
</tr>
<tr>
<td></td>
<td>13.5 (3.7)</td>
<td>27.6 (22.0)</td>
</tr>
<tr>
<td></td>
<td>13.0 (4.4)</td>
<td>6.9 (3.2)*</td>
</tr>
<tr>
<td></td>
<td>1331.6 (355.6)</td>
<td>1335.5 (531.5)</td>
</tr>
<tr>
<td></td>
<td>73.8 (11.8)</td>
<td>140.3 (58.9)*</td>
</tr>
<tr>
<td></td>
<td>7 (4)</td>
<td>12 (6)*</td>
</tr>
</tbody>
</table>

Fig 4 Mean (bold) and individual concentration–time profiles in plasma after epidural administration of ropivacaine (50 mg) and bupivacaine (30 mg) with and without epinephrine.
implantation of the catheters) allowing only two or three consecutive injections. Since we did not know if the effect of epinephrine could be long lasting, we decided to inject first plain drug, and then the drug with epinephrine. A randomised administration would have led to a better protocol, but we did not want to take the risk that our data could be biased by epinephrine from the preceding injection. However, in the ropivacaine experiment which was performed first, we made a third injection with plain drug that showed that the epidural drug disposition returned to normal state (without epinephrine), confirming the validity of our experimental model.

**Haemodynamic evaluation**

There was no visual evidence of CSF leakage after intrathecal catheter insertion confirming that the intrathecal space remained closed. The lack of a systemic effect (i.e. tachycardia) of epinephrine at a dose usually used clinically (5 μg ml\(^{-1}\)) may suggest that the action of epinephrine in this animal model was located mainly in the epidural site. On the other hand, the local action of epinephrine did not lead to increased sympathetic blockade as suggested by the lack of significant haemodynamic difference with or without epinephrine for bupivacaine and ropivacaine.

**Pharmacokinetic evaluation**

Influence of epidurally co-administered epinephrine was similar for ropivacaine and bupivacaine, although more pronounced for the latter. After epidural administration of ropivacaine 50 mg, the ratio between epidural AUC and intrathecal AUC was 6.3. A similar ratio (5.7) was found after the administration of 100 mg of ropivacaine\(^{24}\) suggesting that there was no dose-effect on transmeningeal uptake (\(P=0.37\)).

The pharmacokinetics of epidural bupivacaine and ropivacaine were in accordance with a previous study of our group carried out in a rabbit model.\(^{25}\) Indeed, after epidural administration, the clearance, \(V_{ss}\), and \(T_{1/2}\) of bupivacaine were higher than that of ropivacaine (Table 3).

The dose-normalized epidural AUC for ropivacaine was 2.3 times higher than that for bupivacaine [1230 (255) vs 532 (189) min μg ml\(^{-1}\)]. However, in the intrathecal space, the dose-normalized AUC was 3.5-fold greater for ropivacaine than for bupivacaine [195 (70) vs 56 (33) min μg ml\(^{-1}\)]. These proportions were similar when the local anaesthetics were co-administered with epinephrine, suggesting that the action of epinephrine had no intrinsic effect *per se* on transmeningeal diffusion of ropivacaine and bupivacaine.

The differences (×2.3) in the dose-normalized epidural AUC of these drugs could be explained by the difference in their diffusion into epidural fat, with a two-fold higher diffusion for bupivacaine compared with ropivacaine.\(^{14}\) The increase in the intrathecal dose-normalized AUC was higher (×3.5), in favour of ropivacaine. Such a difference in unbound (i.e. pharmacologically active) intrathecal concentrations may result from an increase in the epidural AUC and also from a difference in protein binding. Indeed, CSF contains acid alpha-glycoprotein and the free fraction of ropivacaine in plasma resulting mainly from binding to that protein (8.2%) is higher than that for bupivacaine (4.4%).\(^{26}\)

The influence of epinephrine on epidural drug disposition has frequently been studied by measuring plasma concentrations. However, this evaluation is indirect, and only evaluates the influence on absorption into the systemic circulation, and not absorption in the CSF. Moreover, as previously reported, the effect of epinephrine on the systemic uptake of epidural drugs is unclear.\(^{6,10,23,27,28}\)

The current evaluation of both epidural and intrathecal concentrations of local anaesthetics brings some new findings to the understanding of the mechanism of action of epidural epinephrine. After epidural administration, local anaesthetics have a low intrathecal bioavailability\(^{23,24,29}\) indicating that almost 90% of the administrated dose is absorbed directly into the systemic circulation.

Our data showed that the effect of epinephrine was more pronounced on bupivacaine than ropivacaine. Indeed, the increase in epidural AUC was higher for bupivacaine than for ropivacaine (52 vs 31%) and plasma concentrations were only modified for bupivacaine, with a significant decrease in Cmax (−37.7%) and a trend towards a decrease in AUC (−28.4%, \(P=0.06\)).

---

**Table 5** Plasma pharmacokinetic parameters after epidural administration. *\(P<0.05\) difference between plain ropivacaine and ropivacaine with epinephrine and between plain bupivacaine and bupivacaine with epinephrine

<table>
<thead>
<tr>
<th></th>
<th>Ropivacaine (50 mg)</th>
<th>Bupivacaine (30 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plain</td>
<td>With epinephrine</td>
</tr>
<tr>
<td>AUC(_{0-120}) (ng min ml(^{-1}))</td>
<td>6241 (2113)</td>
<td>5931 (2227)</td>
</tr>
<tr>
<td>Cmax (mg ml(^{-1}))</td>
<td>86 (49)</td>
<td>103 (60)</td>
</tr>
<tr>
<td>Tmax (min)</td>
<td>13 (4)</td>
<td>17 (21)</td>
</tr>
<tr>
<td>CI/F (ml min(^{-1}))</td>
<td>3.8 (1.8)</td>
<td>3.8 (1.9)</td>
</tr>
<tr>
<td>Vss/F (ml)</td>
<td>669 (217)</td>
<td>828 (352)</td>
</tr>
<tr>
<td>T1/2(_{B}) (min)</td>
<td>139 (79)</td>
<td>170 (68)</td>
</tr>
<tr>
<td>Clast (mg ml(^{-1}))</td>
<td>34 (8)</td>
<td>36 (14)</td>
</tr>
</tbody>
</table>
The differences observed between bupivacaine and ropivacaine on epidural and plasma concentrations could be explained by intrinsic vasoconstrictor properties of ropivacaine compared with bupivacaine.\textsuperscript{16–18} In addition, local anaesthetic action on spinal and peripheral vessels was reported to be concentration-dependent.\textsuperscript{17,19} Recently, in a rat model, it was shown that the combination of ropivacaine and epinephrine did not reduce nerve blood flow to a greater extent than ropivacaine alone.\textsuperscript{19} Hence, it may be assumed that, at the concentration used in our experiment, close to that used clinically (0.33%), ropivacaine induced a vasoconstrictor effect that reduced the effect of epinephrine on its systemic uptake.

Although the increase in epidural AUC was different between ropivacaine and bupivacaine, it resulted in a proportional increase in AUC in the intrathecal space. Indeed, the increase in the intrathecal AUC was 21\% for ropivacaine and 37\% for bupivacaine (\(P=0.07\)). The increase in epidural AUC resulted from a decrease in epidural clearance and distribution (Table 3), allowing a higher uptake of ropivacaine and bupivacaine into the intrathecal space.

The current data suggest that local vasoconstriction of epidural vessels induced by epinephrine influenced the spinal pharmacokinetics of ropivacaine and bupivacaine. However, the spinal pharmacokinetics of drugs is complex and sometimes not intuitive. After epidural administration, drug fate results from different competitive processes,\textsuperscript{13,25,30} such as transmeningeal uptake into the intrathecal space, distribution into epidural fat, and uptake into the systemic circulation. In our study, epidural epinephrine led to a decrease in clearance of ropivacaine and a decrease in distribution of bupivacaine in the epidural space, leading to an increased uptake into the intrathecal space. The impact on systemic uptake was only apparent for bupivacaine. This could result from the fact that bupivacaine is more lipophilic, and has no vasoconstrictor effect compared with ropivacaine.

For both drugs, intrathecal Cl/F decreased significantly with epidurally co-administered epinephrine (Table 4). Considering that epidural epinephrine should not influence intrathecal clearance of local anaesthetics (significant metabolism of epinephrine by meninges\textsuperscript{31}), decreases in Cl/F (from 3.8 to 2.4 ml min\textsuperscript{-1}, around 60\%) should reflect the increase in bioavailability (F). We have previously shown that the mean intrathecal bioavailability of epidural ropivacaine was about 11\%.\textsuperscript{24} Hence, intrathecal bioavailability of epidural ropivacaine administered with epinephrine could be extrapolated to 17.6\%, suggesting a 60\% increase in intrathecal bioavailability. Such an increase may explain the clinical improvement in onset, duration, and intensity of the sensory and motor block of epidural local anaesthetics with epinephrine.

In conclusion, the current work has shown that epidural epinephrine significantly increased the concentrations of ropivacaine and bupivacaine in the epidural space and increased their uptake into the intrathecal space. The action of epinephrine was more pronounced on bupivacaine than ropivacaine, as a result probably of the intrinsic vasoconstrictor property of ropivacaine.

Acknowledgements
The authors thank Professor Frantz Langlais for obtaining the surgery room facilities and M. David Bec for his valuable technical assistance during all animal experiments.

Funding
Institut nationale de la santé et de la recherche médical (INSERM) (CreS 2001 No.4CR02G).

References
1 Sinnott CJ, Cogswell LP III, Johnson A, Strichartz GR. On the mechanism by which epinephrine potentiates lidocaine's peripheral nerve block. Anesthesiology 2003; 98: 181–8
7 Kopacz DJ, Helman JD, Nussbaum CE, Hsiang JN, Nora PC, Allen HW. A comparison of epidural levobupivacaine 0.5\% with or without epinephrine for lumbar spine surgery. Anesth Analg 2001; 93: 755–60
9 Cederholm I, Anskar S, Bengtsson M. Sensory, motor and sympathetic block during 0.5 and 0.75\% ropivacaine with or without epinephrine. Reg Anesth 1994; 19: 18–33
12 Dahl V, Hagen I, Koss KS, Nordentoft J, Reader JC. Bupivacaine 2.5 mg/ml versus bupivacaine 0.625 mg/ml and sufentanil 1 \(\mu g/ml\) with or without epinephrine 1 \(\mu g/ml\) for epidural analgesia in labour. Int J Obstet Anesth 1999; 8: 155–60
31 Kern C, Mautz DS, Bernards CM. Epinephrine is metabolized by the spinal meninges of monkeys and pigs. *Anesthesiology* 1995; 83: 1078–81